loading page

Establishing a surrogate model for inactivation of enveloped viruses to screen viral clearance conditions during biotherapeutics process development
  • +4
  • Hasin Feroz,
  • Daniel Cetnar,
  • Robert Hewlett,
  • Satish Sharma,
  • Melissa Holstein,
  • Sanchayita Ghose,
  • Zheng Jian Li
Hasin Feroz
Bristol-Myers Squibb Co

Corresponding Author:[email protected]

Author Profile
Daniel Cetnar
Penn State University Park
Author Profile
Robert Hewlett
Bristol-Myers Squibb Co
Author Profile
Satish Sharma
Bristol-Myers Squibb Co
Author Profile
Melissa Holstein
Bristol-Myers Squibb Co
Author Profile
Sanchayita Ghose
Bristol-Myers Squibb
Author Profile
Zheng Jian Li
Bristol-Myers Squibb
Author Profile


Viral surrogates to screen for virus inactivation (VI) can be a faster, cheaper and safer alternative to third-party testing of pathogenic BSL2 (Biosafety Level 2) model viruses. Although the bacteriophage surrogate, Ø6, has been used to assess low pH BSL2 VI, it has not been used for evaluation of detergent-mediated VI. Furthermore, Ø6 is typically assayed through host cell infectivity which introduces the risk of cross-contaminating other cell lines in the facility. To circumvent contamination, we developed an in-house RT-qPCR (reverse transcriptase quantitative polymerase chain reaction) assay for selective detection of active Ø6 from a population of live and dead phage. The RT-qPCR assay was used to evaluate Ø6 inactivation in cell culture fluid of monoclonal antibody and fusion protein. Complementary Ø6 infectivity was also conducted at a third-party testing facility. The Ø6 RT-qPCR and infectivity data was modeled against VI of three BSL2 viruses, X- MuLV, A- MuLV and HSV-1 in corresponding therapeutics. Both Ø6 methods demonstrate that any VI agent showing Ø6 clearance of ≥ 2.5 logs would demonstrate complete BSL2 VI of ≥ 4.0 logs. Compared to BSL2 virus testing, this in-house Ø6 RT-qPCR tool can screen VI agents at 5% the cost and a turnaround time of 2-3 days versus 4-7 months.
02 Apr 2021Submitted to Biotechnology Journal
02 Apr 2021Submission Checks Completed
02 Apr 2021Assigned to Editor
06 Apr 2021Reviewer(s) Assigned
16 Jul 2021Editorial Decision: Revise Minor
27 Jul 20211st Revision Received
28 Jul 2021Submission Checks Completed
28 Jul 2021Assigned to Editor
28 Jul 2021Reviewer(s) Assigned
09 Aug 2021Editorial Decision: Revise Minor
16 Aug 20212nd Revision Received
17 Aug 2021Submission Checks Completed
17 Aug 2021Assigned to Editor
17 Aug 2021Reviewer(s) Assigned
01 Sep 2021Editorial Decision: Revise Minor
03 Sep 20213rd Revision Received
06 Sep 2021Assigned to Editor
06 Sep 2021Submission Checks Completed
06 Sep 2021Reviewer(s) Assigned
07 Sep 2021Editorial Decision: Accept